In addition, though varying among cohorts, PAPPA2 mutation rates in the NSCLC set (14.67%–17.86%) are much higher than Asian cohorts, like Ayako Suzuki et al cohort (Japanese, 7.7%) and China cohort (Chinese, 7.1%). Here, PAPPA2 is linked to non-small cell lung carcinoma.